AMA
Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Gastroenterology Review/Przegląd Gastroenterologiczny. 2017;12(3):169-174. doi:10.5114/pg.2017.70468.
APA
Kaniewska, M., Moniuszko, A., & Rydzewska, G. (2017). The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Gastroenterology Review/Przegląd Gastroenterologiczny, 12(3), 169-174. https://doi.org/10.5114/pg.2017.70468
Chicago
Kaniewska, Magdalena, Andrzej Moniuszko, and Grażyna Rydzewska. 2017. "The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis". Gastroenterology Review/Przegląd Gastroenterologiczny 12 (3): 169-174. doi:10.5114/pg.2017.70468.
Harvard
Kaniewska, M., Moniuszko, A., and Rydzewska, G. (2017). The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Gastroenterology Review/Przegląd Gastroenterologiczny, 12(3), pp.169-174. https://doi.org/10.5114/pg.2017.70468
MLA
Kaniewska, Magdalena et al. "The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 12, no. 3, 2017, pp. 169-174. doi:10.5114/pg.2017.70468.
Vancouver
Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Gastroenterology Review/Przegląd Gastroenterologiczny. 2017;12(3):169-174. doi:10.5114/pg.2017.70468.
